PNC Financial Services Group’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.5K Sell
21,871
-1,139
-5% -$1.4K ﹤0.01% 3762
2026
Q2
$28.3K Buy
23,010
+5,699
+33% +$5.68K ﹤0.01% 3624
2026
Q1
$12.2K Buy
17,311
+9,606
+125% +$8.97K ﹤0.01% 3883
2025
Q4
$11.9K Buy
7,705
+24
+0.3% +$38 ﹤0.01% 3878
2025
Q3
$12.1K Buy
7,681
+441
+6% +$766 ﹤0.01% 3858
2025
Q2
$15.8K Sell
7,240
-17,564
-71% -$42.5K ﹤0.01% 3679
2025
Q1
$67.7K Buy
24,804
+688
+3% +$2.71K ﹤0.01% 2918
2024
Q4
$100K Sell
24,116
-72
-0.3% -$272 ﹤0.01% 2675
2024
Q3
$94.1K Buy
24,188
+4,901
+25% +$20.6K ﹤0.01% 2702
2024
Q2
$75.6K Buy
19,287
+13,032
+208% +$56.1K ﹤0.01% 2799
2024
Q1
$26.2K Hold
6,255
– – ﹤0.01% 3303
2023
Q4
$29.4K Buy
+6,255
New +$24.4K ﹤0.01% 3227

Other funds holding MXCT

PNC Financial Services Group's MXCT Position: Q3 2026 in Review

PNC Financial Services Group reduced its MaxCyte (MXCT) stake by 5% in Q3 2026, selling an estimated $1.4K and leaving 21,871 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

PNC Financial Services Group first reported a position in MXCT in Q4 2023 and has held it in 12 quarters since. The position peaked at $100K in Q4 2024. 81 funds tracked by Wall St. Rank hold MXCT as of Q3 2026.

  • PNC Financial Services Group held 21,871 shares of MaxCyte worth $24.5K as of Q3 2026.
  • PNC Financial Services Group sold 1,139 MaxCyte shares in Q3 2026, an estimated $1.4K.
  • MaxCyte made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3762 holding.
  • PNC Financial Services Group first reported a position in MaxCyte in Q4 2023 and has held it in 12 quarters since.
  • PNC Financial Services Group's MaxCyte position peaked at $100K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held MaxCyte as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.